The National Pharmaceutical Pricing Authority (NPPA), on April 2026, under the Drugs (Prices Control) Order, 2013, has computed the retail price of a fixed-dose combination (FDC) comprising:
Relugolix 40 mg + Estradiol 1 mg + Norethindrone Acetate 0.5 mg.
The formulation is manufactured by Macmillon Pharmaceuticals Pvt Ltd and marketed by Aristo Pharmaceuticals Pvt Ltd.
Price Computation Summary:
Relugolix 40 mg (Derived): ₹93.73
Estradiol 1 mg: ₹12.27
Norethindrone 0.5 mg (Derived): ₹1.53
Total (A+B+C): ₹107.53
Less Adjustment (20% deduction): ₹0.31
Worked-out Price: ₹107.22
Claimed Price by Company: ₹137.45
Final Proposed Retail Price: ₹107.22 per tablet (excluding GST)
Basis of Calculation:
Derived prices are computed using the Pronab Sen Committee formula for different strengths.
The final price is the lower of worked-out price and claimed price, as per DPCO norms.
Impact:
The notified price ensures price rationalization and affordability, preventing overpricing of combination drugs while maintaining regulatory compliance.
[Notification No. 19(5080)/2026/DP/NPPA/Div.II]
